Cassava Sciences, Inc.
SAVACassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Simufilam
Alzheimer Disease
Simufilam 100 mg oral tablet
Alzheimer Disease
Simufilam 100 mg tablet
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Simufilam | Phase 3 | Alzheimer Disease | - | - |
Simufilam 100 mg oral tablet | Phase 2 | Alzheimer Disease | - | - |
Simufilam 100 mg tablet | Phase 2 | Alzheimer Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Cassava Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cassava Sciences, Inc.'s (SAVA) pipeline across Phase 3, Phase 2. Its lead program is Simufilam (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cassava Sciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cassava Sciences, Inc. (SAVA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SAVA biotech catalysts?→
Add SAVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cassava Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.